Actinogen Medical Ltd
ASX:ACW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Actinogen Medical Ltd
ASX:ACW
|
AU |
|
InTiCa Systems AG
XETRA:IS7
|
DE |
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
AU |
|
T
|
Tien Wah Press Holdings Bhd
KLSE:TIENWAH
|
MY |
|
E
|
Ecarx Holdings Inc.
NASDAQ:ECX
|
CN |
|
Ubisoft Entertainment SA
PAR:UBI
|
FR |
|
J
|
Jhonlin Agro Raya PT Tbk
IDX:JARR
|
ID |
|
Capcom Co Ltd
OTC:CCOEF
|
JP |
Actinogen Medical Ltd
Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in developing treatment for cognitive impairment associated with neurological diseases of raised cortisol levels inside brain cells. The firm's lead drug candidate, Xanamem, has been designed to block the production of cortisol the stress hormone in the brain. Xanamem is a unique inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the central nervous system. The company is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in neuropsychiatric diseases. The firm focuses on developing Phase II clinical trial evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease.
Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in developing treatment for cognitive impairment associated with neurological diseases of raised cortisol levels inside brain cells. The firm's lead drug candidate, Xanamem, has been designed to block the production of cortisol the stress hormone in the brain. Xanamem is a unique inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the central nervous system. The company is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in neuropsychiatric diseases. The firm focuses on developing Phase II clinical trial evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease.
